clinical trial · NCT06961188
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 174
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene NegativityUntreated With Systemic TherapyNano-crystalline Megestrol Acetate Oral SuspensionStandard Therapy
brief summary
The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and pre-cachexia. The enrolled patients were those with advanced NSCLC who had not received therapy, negative for driver genes and ineligible for curative treatment, and were planned to receive PD-1 inhibitors in combination with platinum-based chemotherapy.
started
Jun 1, 2025
primary completion
Jun 30, 2027
completion
Dec 31, 2027
last updated
May 7, 2025
official title
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in First-Line Non-Squamous Non-Small Cell Lung Cancer Patients During Pre-Cachexia and Cachexia Stages.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol